Assessing Knowledge, Attitude, and Practices towards Ivermectin Pre-exposure Prophylaxis for COVID-19 among Health Care Workers.

Background: Health care workers (HCWs) are more likely to be at high risk of SARS-CoV-2 infection due to their direct and/or indirect participation in treatment facilities. Here, we aimed to evaluate the knowledge, attitude, and practices of ivermectin pre-exposure prophylaxis (PEP) in HCWs. Materials and Methods: In this observational study HCWs who were directly/indirectly involved in the medication of COVID-19 patients were selected. The study questionnaire included demographic data; knowledge, attitudes, practices, and associated adverse drug reactions (ADR) after using ivermectin as pre-exposure prophylaxis in COVID-19. Results: The mean age of the selected 306 participants was 34.41 {±standard deviation 4.08}. 66.66% of the participants were men. 15.69% of individuals had co-morbidities. HCWs were about COVID-19, and 94.12% of people know the role of ivermectin as PEP. Additionally, 180 participants (58.82%) realized that ivermectin can cause adverse drug reactions (ADRs). 70.59% of the study-participants admitted that ivermectin has a protective effect on COVID-19, while 62.75% of the participants believed that the PEP benefits of using ivermectin outweigh the risks. 57.37% (n = 210) of HCW used ivermectin and completed the recommended medication process. Eighteen participants (8.57%) experienced adverse reactions and reported to the ADR monitoring center. Conclusion: 70.59% of the studied participants agreed that ivermectin has a protective effect on COVID-19, and 57.37% of the participants have taken ivermectin as PEP. However, 8.57% of the individuals reported ADR, but none of the participants were severe enough to discontinue the drug. [ABSTRACT FROM AUTHOR]